Compounds > fingolimod hydrochloride
Page last updated: 2024-09-02

fingolimod hydrochloride and Complication, Postoperative

fingolimod hydrochloride has been researched along with Complication, Postoperative in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Engel, DR; Franken, L; Hirner, A; Kalff, JC; Knolle, PA; Koscielny, A; Kurts, C; Limmer, A; Maurer, J; Schiwon, M; Schumak, B; Sparwasser, T; Wehner, S1
Boira, JG; Charpentier, B; Kahan, BD; Madsen, S; Mourad, G; Mulgaonkar, S; Nashan, B; Pellet, P; Tedesco-Silva, H; Vanrenterghem, Y; Weimar, W1
Foster, C; Kovarik, JM; Lorber, MI; Tedesco-Silva, H1
Furukawa, Y; Hara, M; Hwang, MW; Iwasaki, A; Matsumori, A; Okada, M; Ono, K; Sasayama, S1
Inobe, M; Konishi, K; Murakami, M; Todo, S; Uede, T; Yamada, A1

Trials

2 trial(s) available for fingolimod hydrochloride and Complication, Postoperative

ArticleYear
FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
    Transplantation, 2005, Jun-15, Volume: 79, Issue:11

    Topics: Adolescent; Adult; Aged; Biopsy; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Infections; Kidney Transplantation; Middle Aged; Mycophenolic Acid; Postoperative Complications; Propylene Glycols; Safety; Sphingosine; Time Factors; Treatment Outcome

2005
Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function.
    Transplantation proceedings, 2006, Volume: 38, Issue:10

    Topics: Drug Therapy, Combination; Everolimus; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Function Tests; Kidney Transplantation; Lymphocyte Count; Postoperative Complications; Propylene Glycols; Sirolimus; Sphingosine

2006

Other Studies

3 other study(ies) available for fingolimod hydrochloride and Complication, Postoperative

ArticleYear
T helper type 1 memory cells disseminate postoperative ileus over the entire intestinal tract.
    Nature medicine, 2010, Volume: 16, Issue:12

    Topics: Animals; Cell Movement; Dendritic Cells; Fingolimod Hydrochloride; Flow Cytometry; Humans; Ileus; Immunologic Memory; Immunosuppressive Agents; Interferon-gamma; Interleukin-12; Macrophages; Mice; Mice, Inbred C57BL; Postoperative Complications; Propylene Glycols; Sphingosine; Statistics, Nonparametric; Th1 Cells

2010
FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation.
    Circulation, 1999, Sep-21, Volume: 100, Issue:12

    Topics: Animals; Coronary Artery Disease; Cyclosporine; Disease Progression; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Interferon-gamma; Interleukin-2; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred DBA; Postoperative Complications; Propylene Glycols; Sphingosine; T-Lymphocytes, Cytotoxic

1999
Combination treatment with FTY720 and CTLA4IgG preserves the respiratory epithelium and prevents obliterative disease in a murine airway model.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2002, Volume: 21, Issue:6

    Topics: Abatacept; Animals; Antigens, CD; Antigens, Differentiation; Bronchiolitis Obliterans; CTLA-4 Antigen; Disease Models, Animal; Fingolimod Hydrochloride; Immunoconjugates; Immunoglobulin G; Immunosuppressive Agents; Lung Transplantation; Mice; Postoperative Complications; Propylene Glycols; Respiratory Mucosa; Sphingosine; Trachea

2002